tbuckley/cabot-search huggingface dataset:
Reticular erythematous mucinosis: a review of patients' characteristics, associated conditions, therapy and outcome in 25 cases
Authors: F. Rongioletti, V. Merlo, S. Riva, E. Cozzani, E. Cinotti, G. Ghigliotti, A. Parodi, J. Kanitakis
Journal: British Journal of Dermatology (2013)

Reticular erythematous mucinosis (REM) is an uncommon disease, the nosology and specific characteristics of which are controversial because most reports deal with single cases or small series.To describe the characteristics of patients with REM regarding demographics, clinical and pathological features, comorbidities, treatment and course.A retrospective and prospective study was conducted on 25 patients diagnosed with REM in the setting of university-affiliated dermatology departments and dermatopathology centres.Of the 25 patients with REM, 16 were women (sex ratio 2 : 1) and the mean age was 46 years. The roles of sun exposure and oral contraceptives were ambiguous. Associated diseases included hypertension (n = 4), malignancies (n = 3), autoimmune diseases (n = 3) and Borrelia infection (n = 1). Immunological studies (including serology and direct immunofluorescence) were noncontributory. The response to antimalarial treatment was good in > 80% of cases. Worsening or recurrence of the lesion after treatment discontinuation, or in the course of the disease, occurred in 31% of patients.We present the largest REM case series to date. The reticular pattern with involvement of the midline of the chest and back, the predilection for middle-aged women, the controversial relationship with photosensitivity and the possible association with other conditions such as malignancies and thyroid dysfunctions are the main characteristics that makes REM a recognizable disease.
Journal: Health Expectations
Authors: M. Wensing
Journal: BMJ (1999)

Blackwell Science, Annual subscription £180 ISSN 1369 6513 Rating: ![Graphic][1]</img>![Graphic][2]</img>![Graphic][3]</img>![Graphic][4]</img> Health Expectations is a new journal, established in 1998 and published quarterly from 1999. It focuses on “things done with the active involvement of patients, users or citizens” rather than “things done to them.” These include “involvement of patients and their advocates in decisions about individual health care; involvement of users and their representatives in service design, delivery, and evaluation; and involvement of consumer advocates and the general public in debates about health care.” The four issues published so far contained 16 research papers, seven “viewpoints” or literature reviews, and 25 reviews of books or resources in … [1]: /embed/inline-graphic-1.gif [2]: /embed/inline-graphic-2.gif [3]: /embed/inline-graphic-3.gif [4]: /embed/inline-graphic-4.gif
Rapid Response Team Implementation and Hospital Mortality Rates
Authors: John H. Sherner
Journal: JAMA (2009)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Cardiotrophin-1, a Cytokine Present in Embryonic Muscle, Supports Long-Term Survival of Spinal Motoneurons
Authors: D Pennica, V Arce, T.A Swanson, R Vejsada, R.A Pollock, M Armanini, K Dudley, H.S Phillips, A Rosenthal, A.C Kato, C.E Henderson
Journal: Neuron (1996)
Book Review The Immunological Basis of Asthma (Lung Biology in Health and Disease. Vol. 174.) Edited by Bart N. Lambrecht, Henk C. Hoogsteden, and Zuzana Diamant. 800 pp., illustrated. New York, Marcel Dekker, 2003. $195. 0-8247-0882-2
Authors: Gerald J. Gleich
Journal: New England Journal of Medicine (2004)
A primary malarial infection is composed of a very wide range of genetically diverse but related parasites.
Authors: P Druilhe, P Daubersies, J Patarapotikul, C Gentil, L Chene, T Chongsuphajaisiddhi, S Mellouk, G Langsley
Journal: Journal of Clinical Investigation (1998)

To address the question of how many distinct parasites are injected when a mosquito bites, we have characterized isolates resulting most probably from a single sporozoite inoculum. We describe the direct and immediate cloning on hepatocyte feeder layers of a Thai and an African Plasmodium falciparum primary isolate and the characterization of 67 independent clones by four techniques totaling nine different markers. This led to three main conclusions: (a) both the phenotypic and genotypic markers revealed an unexpectedly large degree of diversity within the clones from a single isolate; (b) the clones are nonetheless genetically related; and (c) a single mosquito inoculum would most likely be sufficient to generate considerable isolate complexity in the absence of repeated exposure. This diversity, which has been greatly underestimated in previous studies, does not bode well for the development of successful malaria control means.
692 IMO-2125, AN AGONIST OF TLR9, THAT INDUCES ENDOGENOUS IFN-α UPREGULATES BROADER RANGE OF GENE EXPRESSION PROFILES COMPARED TO EXOGENOUSLY ADDED IFN-α IN HUMAN PBMCS
Authors: W. Jiang, L. Bhagat, D. Yu, E.R. Kandimalla, S. Agrawal
Journal: Journal of Hepatology (2010)
Abstract P3-14-24: Overall Survival Benefit Observed with Lapatinib (L) Plus Paclitaxel (P) as First-Line Therapy in Patients with HER2-Overexpressing Metastatic Breast Cancer (MBC)
Authors: Z-z Guan, B-h Xu, W Arpornwirat, Z-s Tong, V Lorvidhaya, L Wang, B Newstat, M DeSilvio, Y Moore, Z-Z. Shen
Journal: Cancer Research (2010)

Abstract Background: Lapatinib (L) is a potent, oral selective, reversible, inhibitor of EGFR (ErbB1) and HER2 (ErbB2) receptor tyrosine kinases. EGF104535 is a phase III, international, randomized, double-blind study comparing lapatinib plus paclitaxel (L+P) versus P alone as 1st linetreatment for pts with HER2-positive+ (MBC). The study was focused in the Asia Pacific region. Methods: Pts with centrally confirmed HER2-positive (by FISH) MBC and measurable disease were randomized to L 1500 mg daily + P 80mg/m2/wk 3 out of 4 wk or to P 80mg/m2/wk 3 out of 4 wk alone. Pts were administered P for 6 cycles with additional cycles at investigator discretion, and continued on blinded randomized therapy until disease progression (PD). At time of PD, there was an optional monotherapy extension to allow pts on P alone arm to receive L monotherapy. The primary endpoint of the study was overall survival (OS); secondary endpoints included progressionfree survival (PFS), overall response rate (ORR), clinical benefit rate (CBR) and safety. Analyses were conducted on the intent-to-treat population. Results: 444 pts (N=222/arm) across 43 centers were randomized: 67% of P pts received L monotherapy. Baseline demographics were well-balanced between treatment groups. OS was significantly longer in the combination therapy (L+P) as compared with P alone. [Cox Regression Analysis: Treatment Hazard Ratio (HR) (95% CI)=0.64(0.49,0.82), p=0.0005, Kaplan-Meier estimates: median OS 27.8 mos (95% CI=23.2,32.2) vs 20.5 mos (95% CI=17.9,24.3), respectively]. Median PFS increased to 9.7 mos (95% CI=9.2, 11.1) compared with 6.5 mos (95% CI=5.5, 7.3), in the L+P vs P, respectively [HR (95%CI)=0.52(0.42,0.64), stratified log rank P&amp;lt;0.0001]. ORR for L+P was 69% (95% CI=63%,75%) compared with 50% (95% CI=43%,56%) for P alone [Odds Ratio=2.3 (1.54, 3.47), P&amp;lt;0.0001]. CBR improved with L+P (75%, 95% CI=69%,80%) compared with P alone (56%, 95% CI=49%,63%) [Odds Ratio=2.34 (1.54, 3.58), P&amp;lt;0.0001]. The most frequent adverse events (AEs) were diarrhea (L+P, 77%, Grade 3/4 20/0; P, 29% Grade 3/4, &amp;lt;1/&amp;lt;1) and neutropenia (L+P, 77% Grade 3/4, 35/16; P, 47%, Grade 3/4, 15/5). The incidence of withdrawal from treatment due to AEs (13% vs 10%) was a similar. Conclusion: The combination of L+P showed a statistically and clinically meaningful survival advantage. Secondary endpoints support the observed clinical benefit. The combination of L+P was well tolerated. Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P3-14-24.
PREVALENCE OF STREPTOCOCCI AND STAPHYLOCOCCI IN LESIONS OF IMPETIGO
Authors: W.C. Noble, D. Presbuky, B.L. Connor, J.A. Savin, D. Taplin, Lyle Lansdell
Journal: British Journal of Dermatology (1974)

Journal Article PREVALENCE OF STREPTOCOCCI AND STAPHYLOCOCCI IN LESIONS OF IMPETIGO Get access W.C. Noble, W.C. Noble St John's Hospital for Diseases of the Skin, London Search for other works by this author on: Oxford Academic Google Scholar D. Presbuky, D. Presbuky St John's Hospital for Diseases of the Skin, London Search for other works by this author on: Oxford Academic Google Scholar B.L. Connor, B.L. Connor St Thomas' Hospital, London Search for other works by this author on: Oxford Academic Google Scholar J.A. Savin, J.A. Savin Royal Infirmary, Edinburgh Search for other works by this author on: Oxford Academic Google Scholar D. Taplin, D. Taplin University of Miami, Florida, U.S.A Search for other works by this author on: Oxford Academic Google Scholar Lyle Lansdell Lyle Lansdell University of Miami, Florida, U.S.A Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 91, Issue 1, 1 July 1974, Pages 115–116, https://doi.org/10.1111/j.1365-2133.1974.tb06728.x Published: 01 July 1974
Safety and pharmacokinetics of recombinant factor XIII-A2 administration in patients with congenital factor XIII deficiency
Authors: Amy E. Lovejoy, Tom C. Reynolds, Jennifer E. Visich, Michael D. Butine, Guy Young, Melissa A. Belvedere, Rachelle C. Blain, Susan M. Pederson, Laura M. Ishak, Diane J. Nugent
Journal: Blood (2006)
Isolated del(5q) in myeloid malignancies: Clinicopathologic and molecular features in 143 consecutive patients
Authors: Mrinal M. Patnaik, Terra L. Lasho, Christy M. Finke, Ryan A. Knudson, Rhett P. Ketterling, Dong Chen, James D. Hoyer, Curtis A. Hanson, Ayalew Tefferi
Journal: American Journal of Hematology (2011)

World Health Organization (WHO) criteria were used to identify 143 consecutive patients (median age 73 years; 90 females) with myeloid neoplasms and isolated del(5q) seen between 1989 and 2009. We have previously reported on 88 (61%) of these patients who met criteria for WHO defined "myelodysplastic syndromes (MDS) with isolated del(5q)." The remaining 55 patients were classified as having "other" MDS variants (n = 29; 20%), acute myeloid leukemia (AML; n = 14; 10%), or myeloproliferative neoplasms (MPN; n = 12; 8%). DNA was available in 138 patients and mutation screening revealed 20 cases with JAK2, 6 with IDH, and 3 with MPL mutations; JAK2 and MPL mutations were seen mostly in MPN or "MDS with isolated del(5q)" whereas IDH mutations were frequent in other MDS variants. Overall median survival for the 143 patient cohort was 35 months and leukemic transformation (LT) was documented in 19 (~13%) cases. "MDS with isolated del(5q)" had the best prognosis with median survival of 66 months and LT rate of ~6%. Survival was poor among the other myeloid neoplasm subgroups regardless of specific morphologic diagnosis. Multivariable analysis identified higher leukocyte count and percentage of bone marrow and circulating blasts as independent predictors of shortened survival. The first two parameters and the presence of IDH mutations predicted inferior leukemia-free survival. The current study validates the prognostic relevance of considering "MDS with isolated del(5q)" as a separate WHO subcategory and identifies leukocytosis, higher blast count, and IDH mutations as being prognostically detrimental, in myeloid neoplasms associated with isolated del(5q).
Diphenylhydantoin Prevention of Arrhythmias in the Digitalis-Sensitized Dog after Direct-Current Cardioversion
Authors: RICHARD H. HELFANT, BENJAMIN J. SCHERLAG, ANTHONY N. DAMATO
Journal: Circulation (1968)

The ability of diphenylhydantoin to prevent arrhythmias induced by synchronized direct current shocks after digitalis sensitization was evaluated. In the control state, an average of 155 watt-seconds was required to produce ventricular tachycardia. Immediately after recovery from digitalis toxicity, an average of 23 watt-seconds produced ventricular tachycardia. The administration of diphenylhydantoin at this time immediately increased the threshold required for ventricular tachycardia to an average of 363 watt-seconds. In eight studies, diphenylhydantoin was given during cardioversion-induced ventricular tachycardia and converted all cases to regular sinus rhythm. These findings indicate that diphenylhydantoin may be of prophylactic value prior to direct current cardioversion in a digitalized patient. Conversely, diphenylhydantoin would also be useful in the management of ectopic beats that may occur in digitalized patients after cardioversion.
Faculty Tracks and Academic Success
Authors: William N. Kelley, Jeoffrey K. Stross
Journal: Annals of Internal Medicine (1992)

In 1977, the Department of Internal Medicine at the University of Michigan implemented two specific faculty career tracks, the physician-scientist and clinician-scholar, to define more clearly the goals and expectations to which individuals should strive to achieve academic success. In response to the changing environment, a leadership track and a full-time clinical track were added. Although concerns about comparability, transfer between tracks, and research productivity were raised initially, they were alleviated as it became apparent that the ability to achieve tenure was similar in the physician-scientist and clinician-scholar tracks. The development of well-defined faculty tracks has facilitated the alignment of talents, training, and effort with career goals. It has also enabled us to protect the time of young investigators to pursue their research activities and to define the expectations for promotion for clinicians with a major commitment to patient care.
Studies Probe Role of Telomere Length in Predicting, Modulating Cancer Risk
Authors: Tracy Hampton
Journal: JAMA (2011)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE IMPORTANCE OF GLUTATHIONE IN THE FORMATION OF STABLE TECHNETIUM −99m LABELED LIPOSOMES USING THE LIPOPHILIC CHELATOR HEXAM ETHYL-PROPYLENE AMINE OXIME
Authors: B. Goins, R. Klipper, A. S. Rudolph, J. H. Timmons, R. Blumhardt, W. T. Phillips
Journal: Clinical Nuclear Medicine (1992)

S: APRIL 9–12, 1992 San Antonio Convention Center & Hyatt Regency Hotel SAN ANTONIO, TEXAS Southwestern Chapter Society of Nuclear Medicine SPECT/PET Nuclear Cardiology Symposium and 37th Annual Meeting: PDF Only
Accuracy, Safety, and Tolerability of Tissue Collection by Cytosponge vs Endoscopy for Evaluation of Eosinophilic Esophagitis
Authors: David A. Katzka, Debra M. Geno, Anupama Ravi, Thomas C. Smyrk, Pierre Lao-Sirieix, Ahmed Miramedi, Irene Debiram, Maria O’Donovan, Hirohito Kita, Gail M. Kephart, Lori A. Kryzer, Michael Camilleri, Jeffrey A. Alexander, Rebecca C. Fitzgerald
Journal: Clinical Gastroenterology and Hepatology (2014)
Follicular dendritic cell sarcoma: A report of 14 cases and a review of the literature
Authors: Andres O. Soriano, Michael A. Thompson, Joan H. Admirand, Luis E. Fayad, Alma M. Rodriguez, Jorge E. Romaguera, Fredrick B. Hagemeister, Barbara Pro
Journal: American Journal of Hematology (2007)

Abstract Follicular dendritic cell sarcomas (FDCS) are grouped with the histiocytic and dendritic cell neoplasms. The natural history and response to different treatments have not been well established. The cases of 14 patients with FDCS who were seen at M. D. Anderson between 1995 and 2005 were reviewed. Median patient age was 48 years (range, 25–69 years). Histologically, four cases showed low‐grade features, three cases showed low‐grade features with focal high‐grade features, and five cases showed high‐grade features. Tumors were positive for CD21, CD23, and CD35 in 83, 90, and 44% of cases, respectively. Twelve (92%) of 13 tumors were strongly positive for epidermal growth factor receptor. Information on initial treatment was available in 11 patients, which included surgery alone in one patient, surgery and radiation in two, surgery and chemotherapy in one, chemotherapy alone in three, chemotherapy and radiation in one, surgery followed by radiation and chemotherapy in three patients. In eight patients the initial chemotherapy regimen was cyclophosphamide, doxorubicin, vincristine, and prednisone. Complete remission was achieved in 7 (63%) of 11 patients. Ten patients were alive at a median follow up of 22 months, 3 (23%) of 13 had no evidence of disease, and 7 (53%) of 13 patients were alive with disease. Follicular sarcoma is an aggressive neoplasm. Although most of the patients initially responded to treatment, the majority of them (81%) relapsed. A better understanding of the biology of FDCS could guide our efforts in the development of new treatment modalities for this rare disease. Am. J. Hematol., 2007. © 2007 Wiley‐Liss, Inc.
Effects of preparation methods on the allergenicity of peanut in a murine model of peanut-induced anaphylaxis
Authors: Hayf Emeil Al-Mussawir, Kamal D Srivastava, Kirsten Beyer, Jin-Hua Li, Side Li, Wesley Burks, Gary A Bannon, Xiu-Min Li, Hugh A Sampson
Journal: Journal of Allergy and Clinical Immunology (2002)
Mortality study of pathologists and medical laboratory technicians.
Authors: J M Harrington, H S Shannon
Journal: BMJ (1975)

Membership lists of professional bodies were used to establish study populations of British pathologists (1955-73) and medical laboratory technicians (1963-73). The standardised mortality ratio (SMR) for pathologists was 60 and for medical laboratory technicians 67. Twenty-seven of the 310 deaths were due to suicide. These numbers gave SMRs of 250 for pathologists and 243 for medical laboratory technicians. Suicide was the commonest cause of death in female technicians. Access to lethal chemicals at work is a possible factor explaining the high proportion of suicide by poisoning compared with the general population. Suicide rates for pathologists exceed those of all medical practitioners; similary medical laboratory have higher rates than all laboratory technicians. Excess deaths from lymphatic and haemopoietic neoplasms were noted in English male pathologists (observed 8, expected 3-3; P less than 0-01). This difference is not due to Hodgkin9s disease or leukaemia and remains unexplained. No other neoplastic diseases were noted as causing excess mortality in either occupational group but a small, possibly spurious, excess number of deaths was noted for aortic aneurysm in male pathologists (observed 4, expected 1-8).
Response to donor lymphocyte infusions for chronic myeloid leukemia is dose-dependent: the importance of escalating the cell dose to maximize therapeutic efficacy
Authors: M P Simula, S Marktel, C Fozza, J Kaeda, R M Szydlo, E Nadal, M Bua, A Rahemtulla, E Kanfer, D Marin, E Olavarria, J M Goldman, J F Apperley, F Dazzi
Journal: Leukemia (2007)
Prevention of Coronary Heart Disease in Practice
Authors: Ernst L. Wynder
Journal: JAMA (1986)

<h3>To the Editor.—</h3> Those working in the area of coronary heart disease prevention read the contribution of Dr Borhani<sup>1</sup>with great interest. The article entitled "Prevention of Coronary Heart Disease in Practice," well summarizes the various intervention trials. There is general agreement that prevention has played an important role and can, if properly applied, have even greater impact on the incidence of coronary artery disease. There is not agreement, however, that in terms of primary prevention, a physician's medical intervention should be limited to the identification of high-risk children or first-degree relatives of patients with established heart disease. Decades ago, Virchow observed that "crowd diseases" by and large do not have a genetic basis but relate to a common factor affecting a sizable proportion of a population. Clearly, this concept applies to coronary artery disease and atherosclerosis. Determining blood lipid levels in children is important not only because so
THE RADICAL CURE OF MALIGNANT TUMORS BY OPERATION.Read in the Section on Surgery and Anatomy at the Forty-fifth Annual Meeting of the American Medical Association, held at San Francisco, June 5-8,1894.
Authors: J. H. WYTHE
Journal: JAMA (1894)

By the phrase, malignant tumor, both the profession and the laity distinguish any new growth which has a direct tendency to destroy life. Malignancy is shown by the rapid invasion of adjoining structures, the enlargement of neighboring lymph glands in which the same kind of tumor is soon produced, and by the formation of similar structures in distant organs from the transfer of morbid germs through the lymphatics and blood vessels. In one or all of these ways, a virulent morbid growth will be manifested, according to the time it has existed and the activity of its growth. Innocent tumors may recur, as well as malignant ones, if they are insufficiently removed by the surgeon, but they are subject to operation, not on account of their destructive virulence, but for the relief of pain, inconvenience or disfigurement. Operations for the removal of malignant tumors may also be useful as palliative,
The therapeutic effect of intralesional interferon in classical Kaposi's sarcoma
Authors: A. TRATTNER, Z. REIZIS, M. DAVID, A. INGBER, J. HAGLER, M. SANDBANK
Journal: British Journal of Dermatology (1993)

Interferon alpha-2a, which has antineoplastic, antiviral, immunomodulatory, and antiangiogenic effects, was evaluated in a prospective study, treating 10 lesions of patients with classical Kaposi's sarcoma. Ten patients received injections of interferon alpha-2a intralesionally in a dose of 3 million units three times weekly for 4 weeks, and in a variable dose for 4 more weeks. Two of the patients had a complete response, and in one of these, distant lesions also responded. Seven had a partial response, and one did not respond. The treatment was generally well tolerated. The results of our study support the use of interferon in the therapy of classical Kaposi's sarcoma, although it would appear that to achieve maximum efficacy, a longer period of treatment is needed.